CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Merced |
Dr. Michelle Khine |
SEED Grant |
Micro Platform for Controlled Cardiac Myocyte Differentiation |
$193,700 |
| University of California, Irvine |
Dr. Michelle Khine |
SEED Grant |
Micro Platform for Controlled Cardiac Myocyte Differentiation |
$156,426 |
| University of California, San Diego |
Dr. Catriona Jamieson |
SEED Grant |
Derivation and Characterization of Cancer Stem Cells from Human ES Cells |
$616,305 |
| University of California, San Francisco |
Dr. Su Guo |
SEED Grant |
Identifying small molecules that stimulate the differentiation of hESCs into dopamine-producing neurons |
$542,619 |
| University of California, San Francisco |
Dr. Linda C. Giudice |
SEED Grant |
Human Embryonic Stem Cell Differentiation to Trophoblast: Basic Biology and Clinical Translation to Improve Human Fertility |
$614,784 |
| University of California, San Francisco |
Dr. Robert Blelloch Dr. |
SEED Grant |
MicroRNA Regulation of Human Embryonic Stem Cell Self-Renewal and Differentiation |
$605,886 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Hudson Freeze |
SEED Grant |
Role of Glycans in Human Embryonic Stem Cell Conversion to Neural Precursor Cells |
$708,000 |
| University of California, San Diego |
Dr Sylvia Evans |
SEED Grant |
Specification of Ventricular Myocyte and Pacemaker Lineages Utilizing Human Embryonic Stem Cells |
$585,600 |
| Salk Institute for Biological Studies |
Dr. Beverly M Emerson Dr. |
SEED Grant |
Regulation of Specific Chromosomal Boundary Elements by CTCF Protein Complexes in Human Embryonic Stem Cells |
$647,343 |
| University of California, Santa Cruz |
Dr. Bin Chen |
SEED Grant |
In vitro differentiation of hESCs into corticospinal motor neurons |
$465,624 |
| Human BioMolecular Research Institute |
Dr. John R Cashman Ph.D. |
SEED Grant |
Discovering Potent Molecules with Human ESCs to Treat Heart Disease |
$688,274 |
| Buck Institute for Age Research |
Dr. Dale E. Bredesen |
SEED Grant |
Programmed Cell Death Pathways Activated in Embryonic Stem Cells |
$728,950 |
| University of California, Los Angeles |
Dr. Douglas L. Black |
Basic Biology II |
Programs of alternative splicing regulation by polypyrimidine tract binding protein |
$1,344,562 |
| University of California, San Diego |
Dong-Er Zhang |
Basic Biology II |
RUNX1 in maintenance, expansion, and differentiation of therapeutic pluripotent stem cells |
$1,371,540 |
| University of California, Irvine |
Professor Marian L Waterman |
Basic Biology II |
TCF-3: A Wnt Pathway Effector and Nanog Regulator in Pluripotent Stem Cell Self-Renewal |
$1,259,879 |
| iPierian, Inc. |
Dr. Irene Griswold-Prenner |
Basic Biology II |
Cellular Reprogramming: Dissecting the Molecular Mechanism and Enhancing Efficiency |
$1,458,000 |
| Palo Alto Veterans Institute for Research |
Dr. Tony Wyss-Coray |
Basic Biology II |
Systemic Protein Factors as Modulators of the Aging Neurogenic Niche |
$1,159,806 |
| Stanford University |
Professor Garry P Nolan |
Basic Biology II |
Kinase signaling analysis of iPS cell reprogramming and differentiation |
$1,343,100 |
| University of California, Los Angeles |
Dr. Benhur Lee |
Basic Biology II |
The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation |
$1,371,936 |
| University of California, Davis |
Dr. Eric A Kurzrock |
Basic Biology II |
Differentiation of Human Embryonic Stem Cells into Urothelium |
$849,037 |
| University of California, Los Angeles |
Dr. Yong Kim |
Basic Biology II |
Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells |
$1,259,371 |
| University of California, San Diego |
Dr. Kun-Liang Guan |
Basic Biology II |
The function of YAP in human embryonic stem cells |
$1,245,693 |
| Stanford University |
Dr. Aaron J Hsueh |
Basic Biology II |
Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation |
$1,309,018 |
| University of California, San Francisco |
Dr. John L Rubenstein |
Basic Biology II |
MGE Enhancers to Select for Interneuron Precursors Produced from Human ES Cells |
$1,387,800 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Huei-sheng Vincent Chen |
Basic Biology II |
Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes |
$1,587,610 |
| University of California, Irvine |
Dr. Aileen J Anderson |
Basic Biology II |
Role of the microenvironment in human iPS and NSC fate and tumorigenesis |
$1,256,194 |
| Stanford University |
Dr. Steven Edward Artandi |
Basic Biology II |
Self-renewal and senescence in iPS cells derived from patients with a stem cell disease |
$931,285 |
| Salk Institute for Biological Studies |
Ronald Mark Evans |
Basic Biology II |
Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs |
$1,712,880 |
| Calimmune, Inc. |
Geoff Symonds |
Disease Team Research I |
GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE |
$8,278,722 |
| Stanford University |
Dr. Gary Steinberg |
Disease Team Research I |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Disease Team Research I |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$5,694,308 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Disease Team Research I |
Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
| University of California, Los Angeles |
Dr. Irvin SY Chen |
Disease Team Research I |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
| ViaCyte, Inc. |
Allan Robins |
Disease Team Research I |
Cell Therapy for Diabetes |
$0 |
| Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Research I |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
| University of California, San Francisco |
Dr. Mitchel S Berger |
Disease Team Research I |
Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
